- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04272255
Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness
February 13, 2020 updated by: Repurposed Therapeutics, Inc.
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of DPI-386 Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness
This multi-site Phase 3 clinical trial is a randomized, double-blind, placebo-controlled and open label active-controlled study to identify the safety and efficacy of a repeated-dose regimen of DPI-386 nasal gel (intranasal scopolamine gel) for the prevention and treatment of motion sickness.
The study will be conducted aboard Navy fleet or Marine ships undergoing military operations to obtain data in an operationally relevant real world environment.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The study will have three arms: DPI-386 nasal gel, placebo nasal gel, and Transderm Scop® (1.5 mg/72 hours; transdermal scopolamine patch [TDS], the current standard of care for the treatment of motion sickness).
The study will include 100 subjects per arm, for a total of 300 subjects (n=300).
Multiple ships and ships' crews will be used, until the required enrollment is completed.
The DPI-386 Nasal Gel and placebo nasal gel arms will be double-blinded, whereas the TDS arm will remain unblinded.
Both DPI-386 Nasal Gel and placebo nasal gel will be administered twice daily over the six consecutive Treatment Days.
The two daily doses of DPI-386 Nasal Gel or placebo nasal gel will be separated by a minimum of six hours ± 15 minutes, and will occur during the subject's on-duty period.
The TDS patch will be administered on Treatment Days 1 and 4.
Study Type
Interventional
Enrollment (Anticipated)
300
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Dayton, Ohio, United States, 45433
- Recruiting
- NAMRU-D
-
Contact:
- Matthew Doubravo, MD
- Phone Number: 937-938-3915
- Email: matthew.doubravo@us.af.mil
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 59 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of signed and dated ICD.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male or female, aged 18 to 59 (inclusive).
- Active duty military or reserves on active status. All potential subjects must be able to provide a current military ID to be viewed by PI or qualified designee prior to signing the ICD.
- At least minimally susceptible to provocative motion as evidenced by a minimum score of 3.0 on the Motion Sickness Susceptibility Questionnaire (MSSQ).
- In good general health as evidenced by medical history with no recent history or current diagnosis of clinical problems as recommended by the PI or qualified designee.
- Ability to take intranasal medication and willingness to adhere to the study schedule and time constraints.
- For females of child-bearing potential: willingness to provide a urine sample for the hCG pregnancy test. Test must be negative.
Agreement to adhere to the following lifestyle compliance considerations:
- Refrain from consumption of grapefruit and any substance containing grapefruit for seven days prior to, during, and for seven days after the six treatment days.
- Abstain from alcohol for 24 hours prior to first dose of study medication and during the six Treatment Days.
Exclusion Criteria:
- Pregnancy, lactation, or positive urine pregnancy test at screening.
- Known allergic reactions to scopolamine or other anticholinergics.
- Currently prescribed any of the following medication types: belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.
- Hospitalization or significant surgery requiring hospital admittance within the past six months.
- Treatment with another investigational drug or other intervention within the past 30 days.
- Having donated blood or plasma or suffered significant blood loss within the past 30 days.
Having any of the following medical conditions within the last two years or deemed clinically significant by the PI or qualified designee as being exclusionary:
- Significant gastrointestinal disorder, asthma, or seizure disorders.
- History of vestibular disorders.
- History of narrow-angle glaucoma.
- History of urinary retention problems.
- History of alcohol or drug abuse.
- Nasal, nasal sinus, or nasal mucosa surgery.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: DPI-386 nasal gel
DPI-386 Nasal Gel is formulated to contain 0.2 mg scopolamine HBr per 0.1 g dose, with each dose therefore described as "0.2 mg / 0.1 g"
|
Nasal Gel
|
Placebo Comparator: placebo nasal gel
Placebo nasal gel product is the same but does not contain scopolamine HBr
|
Nasal Gel
|
Experimental: Transderm Scop®
TDS patch delivers 1.5 mg of scopolamine over a 72-hour period.
TDS arm will apply two TDS patches over the six treatment days.
|
Patch
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of DPI-386 Nasal Gel
Time Frame: 3 days
|
Compare the efficacy of DPI-386 Nasal Gel (0.2 mg scopolamine HBr per dose, maximum of two doses per day, for a maximum of six doses over three consecutive days) with that of the TDS patch and placebo nasal gel in the prevention and treatment of nausea associated with motion sickness.
The efficacy endpoint will be determined by comparing the Motion Sickness Assessment Questionnaire (MSAQ) scores over the treatment period across all three treatment arm.
Sixteen symptoms are listed, with symptoms differentiated along four dimensions: gastrointestinal, central, peripheral, and sopite-related.
Each symptom is scored from 1 to 9 in severity and scores then calculated.
All 16 items were collected from the general public instead of experts, allowing for a more accurate wording of the symptomology experienced by persons outside of hysiological sciences.
|
3 days
|
Safety of DPI-386 Nasal Gel in terms of cognitive effects
Time Frame: 24 hours
|
Compare the safety of DPI-386 Nasal Gel with that of the TDS patch and placebo nasal gel, with an emphasis on cognitive effects by incidence of treatment related adverse events.
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of DPI-386 and severe nausea
Time Frame: 3 days
|
Compare the efficacies of DPI-386 Nasal Gel, TDS patch, and placebo nasal gel in severity of nausea.
Respondents specify their degree of nausea by indicating a point along a continuous 100mm line between two end-points; left one is for "No nausea" and the right one for "Very severe nausea".
Scoring is based on the length from left point and a higher score means more severe degree of nausea.
Severity of nausea will measured by the Nausea Assessment (Visual Analog Scale) (VAS)) over the treatment period.
|
3 days
|
Safety of DPI-386 Nasal Gel in terms of cognition
Time Frame: 24 hours
|
Compare the safety of DPI-386 Nasal Gel with that of TDS patch and placebo nasal gel in terms of cognition as measured by the Psychomotor Vigilance Tests (PVT).
The (PVT) is a neurocognitive assessment that measures alertness and tests sustained attention and reaction time.
It was originally developed for sleep studies, and involves simple reaction time testing by requiring the participant to push a button as soon as the stimulus (a light) appears.
After a response, the reaction time (in ms) is displayed.
The inter-stimulus interval varies from two to 10 seconds, so it is not predictable, and the entire task takes 10 minutes.
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: David Helton, Repurposed Therapuetics, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 22, 2019
Primary Completion (Anticipated)
June 1, 2020
Study Completion (Anticipated)
July 1, 2020
Study Registration Dates
First Submitted
December 14, 2018
First Submitted That Met QC Criteria
February 13, 2020
First Posted (Actual)
February 17, 2020
Study Record Updates
Last Update Posted (Actual)
February 17, 2020
Last Update Submitted That Met QC Criteria
February 13, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Motion Sickness
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Antiemetics
- Gastrointestinal Agents
- Adjuvants, Anesthesia
- Mydriatics
- Scopolamine
- Butylscopolammonium Bromide
Other Study ID Numbers
- DPI-386-MS-08
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Motion Sickness
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness, Space | Motion Simulation | Parabolic FlightUnited States
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness | Sea Sickness | Motion Sickness, SpaceUnited States
-
Faisal_Karmali@MEEI.HARVARD.EDUMassachusetts Institute of Technology; National Space Biomedical Research InstituteCompleted
-
Naval Aeromedical Research Unit, DaytonUnknownPrevention of Nausea Associated With Motion Sickness | Treatment of Nausea Associated With Motion SicknessUnited States
-
Wingate Institute of NeurogastroenterologyCompletedVisually Induced Motion Sickness in Healthy VolunteersUnited Kingdom
-
University Hospital, CaenCompleted
-
United States Army Aeromedical Research LaboratoryAlabama College of Osteopathic Medicine; Department of Aviation Medicine, U...CompletedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.TerminatedMotion SicknessUnited States
-
Dartmouth-Hitchcock Medical CenterRecruiting
-
Vanda PharmaceuticalsRecruitingMotion SicknessUnited States
Clinical Trials on scopolamine HBr
-
Spero TherapeuticsCovanceCompleted
-
Spero TherapeuticsClinartisCompleted
-
Spero TherapeuticsCompleted
-
Repurposed Therapeutics, Inc.Unknown
-
Spero TherapeuticsCompletedHealthy VolunteersUnited States
-
Spero TherapeuticsCompleted
-
Urmia University of Medical SciencesCompletedParoxysmal Atrial Fibrillation | Sick Sinus SyndromeIran, Islamic Republic of
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedMigraine Without Aura | Migraine With AuraSpain, France, Italy, Netherlands, Turkey, Belgium, Hungary, Czechia, Denmark, Germany, Greece, Norway, Portugal, Sweden
-
Bukwang PharmaceuticalTerminatedChronic Hepatitis BKorea, Republic of